Generic Vantrela ER Availability
Last updated on May 7, 2025.
Vantrela ER is a brand name of hydrocodone, approved by the FDA in the following formulation(s):
VANTRELA ER (hydrocodone bitartrate - tablet, extended release;oral)
-
Manufacturer: TEVA BRANDED PHARM
Approval date: January 17, 2017
Strength(s): 15MG (discontinued) [RLD], 30MG (discontinued) [RLD], 45MG (discontinued) [RLD], 60MG (discontinued) [RLD], 90MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vantrela ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Abuse resistant drug formulation
Patent 8,445,018
Issued: May 21, 2013
Inventor(s): Habib Walid A. & Hamed Ehab & Vega Zepeda Manuel A.
Assignee(s): Cima Labs Inc.A pharmaceutical composition may include a coated particulate which may include at least one active pharmaceutical ingredient, particularly one susceptible to abuse by an individual. The coated particles may include a fat/wax and have improved controlled release and/or crush resistance. Method of making these coated particulate and dosage forms therewith are also described.
Patent expiration dates:
- July 31, 2029✓
- July 31, 2029
-
Abuse resistant drug formulation
Patent 9,216,176
Issued: December 22, 2015
Inventor(s): Habib Walid A. & Hamed Ehab & Vega Zepeda Manuel A.
Assignee(s): Cima Labs Inc.A pharmaceutical composition may include a coated particulate which may include at least one active pharmaceutical ingredient, particularly one susceptible to abuse by an individual. The coated particles may include a fat/wax and have improved controlled release and/or crush resistance. Method of making these coated particulate and dosage forms therewith are also described.
Patent expiration dates:
- September 13, 2027✓
- September 13, 2027
-
Abuse resistant drug formulation
Patent 9,572,803
Issued: February 21, 2017
Inventor(s): Habib Walid A. & Hamed Ehab & Vega Zepeda Manuel A.
Assignee(s): Cima Labs Inc.A pharmaceutical composition may include a coated particulate which may include at least one active pharmaceutical ingredient, particularly one susceptible to abuse by an individual. The coated particles may include a fat/wax and have improved controlled release and/or crush resistance. Method of making these coated particulate and dosage forms therewith are also described.
Patent expiration dates:
- September 13, 2027✓
- September 13, 2027
More about Vantrela ER (hydrocodone)
- Vantrela ER consumer information
- Check interactions
- Compare alternatives
- Imprints, shape & color data
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: Opioids (narcotic analgesics)
- Breastfeeding
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.